GlaxoSmithKline (GSK), based in London, is a global healthcare company engaged in the discovery, dev...
Alkermes and the Opioid Crisis
02/02/2018 5:00 am EST
After a rather quiet year in 2017, Alkermes (ALKS) is due for major clinical, regulatory and commercial catalysts in 2018, suggests biotech expert John McCamant, editor of The Medical Technology Stock Letter.
The recent JPMorgan presentation was very well received. With a focus on psychiatry, ALKS is well-positioned to be an integral player in addressing the opioid crisis with Vivitrol, advancing the launch of Aristada and continues to advance its late-stage R&D pipeline.
At least one and maybe two new drugs are expected to gain FDA approval – Aristada’s nanocrystal disperion (NCD) version is due by June 30 and the company’s novel MDD drug ALKS 5461 is set for a Q1:18 NDA filing and possible commercialization by year-end.
With less than 4% share of the opioid dependence market, Vivitrol continues to expand its footprint with broader accessibility and awareness via education. Sales rose 40%+ in 2016/17 and are on track to post sales exceeding $300 million in 2018.
Despite the global attempt to slow the crisis, the deaths by opioid overdoses have not stopped growing. Hence, Vivitrol’s role is still a key place to address opioid overdoses.
Despite being controversial (we believe already discounted into ALKS’s share price), ‘5461 will be filed and reviewed and possibly approved this year. Expectations are mixed at best, so any upside might be well reflected.
ALKS’ recent collaboration with Biogen (BIIB) for a next-generation Tecfidera, ALKS-8700, in our view, reduces risk and helps validate the program and could extend the life cycle for one of Biogen’s key MS drugs with a much cleaner side effect profile and long patent protection.
ALKS could not have garnered a better partner. Taken together, ALKS is due for busy and productive 2018, one that could catapult the Company back into investor’s favor after a flattish 2017. It feels like it could be their turn. Indeed, we see a big year ahead.
Related Articles on HEALTHCARE
iShares S&P Global Healthcare (IXJ) is an exchange-traded fund that seeks to track the S&P G...
We initiated coverage on drug contract research company Icon PLC (ICLR) in May 2016; in 17 months, t...
After a rather quiet year in 2017, Alkermes (ALKS) is due for major clinical, regulatory and commerc...